Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07185971 · ClinicalTrials.gov registry record · NA
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
A NA study of Homonymous Quadrantanopia and Homonymous Hemianopsia, sponsored by NeuroAEye.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07185971 is a NA study of Homonymous Quadrantanopia and Homonymous Hemianopsia that is actively recruiting participants, run by NeuroAEye. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07185971, a NA study of Homonymous Quadrantanopia and Homonymous Hemianopsia, is actively recruiting participants, sponsored by NeuroAEye.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual stimulation to subjects diagnosed with visual field loss. The primary objective is to demonstrate that the clinical outcomes from exposure to the PAVE therapy (test group) are statistically superior to those achieved with a placebo (control group). The primary outcome is an increase in visual field area as measured with Goldmann-type kinetic perimetry. The secondary outcome will be demonstration that the subjective assessment of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) is better for the test group when compared with the control group. The participants will visit the investigators office once per week for a minimum of eight weeks and a maximum of twenty four weeks and receive a therapy session. Every four weeks the participants visual field will be measured using kinetic perimetry. Every eight weeks the participant will complete the NEI-VFQ. Four weeks after the completion of the therapy sessions a follow up visit will take place where visual field measurement using kinetic perimetry and NEI-VFQ will be administered.
Conditions Studied
Interventions
- DEVICE PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
- DEVICE PAVE Placebo
Study Locations (1)
Iowa
- Dr. D. M. Fitzgerald & Associates - Cedar Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2026-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07185971
The ClinicalTrials.gov registry entry for NCT07185971 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroAEye, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Homonymous Quadrantanopia appearing as the primary indexed condition, and to 2 interventions - of which PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display is the first listed.
NCT07185971 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT07185971 about?
NCT07185971 is a clinical study titled "PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery". This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual st...
What is the current status of trial NCT07185971?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-09-22. Estimated completion is 2026-08.
What conditions does trial NCT07185971 study?
This clinical trial studies the following conditions: Homonymous Quadrantanopia, Homonymous Hemianopsia.
What interventions are being tested in trial NCT07185971?
The interventions under investigation include: PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display (DEVICE), PAVE Placebo (DEVICE).
Who is sponsoring clinical trial NCT07185971?
This trial is sponsored by NeuroAEye, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07185971 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homonymous Quadrantanopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.